Relugolix update shared as FDA weighs approval in prostate cancer
Under the Prescription Drug User Fee Act, the FDA is scheduled to make its decision on relugolix by December 20, 2020.
Under the Prescription Drug User Fee Act, the FDA is scheduled to make its decision on relugolix by December 20, 2020.
“PSMA PET imaging is used in the initial diagnostic staging and then in subsequent cases where there can be a recurrence after primary treatment.,” says…
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
“The 1 tweak that’s different for our model is that the trained urologist is watching the cysto at the same time as the nurse practitioner…
“This data should bolster physicians’ confidence in recommending active surveillance for their patients when it is an appropriate option,” says Timothy J. Daskivich, MD.
“Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits…
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
The AssureMDx test demonstrated an area under the curve of 0.80 in detecting urinary tract recurrences in MIBC.
“As most of us know, 1 in 8 couples undergo issues pertaining to fertility, and in about half of those cases, there is a male…
“These results are encouraging and suggest that circulating biomarkers may be useful in guiding the use of radium-223 therapy,” says David T. Miyamoto, MD, PhD.